Given that ATRA is the standard therapeutic agent in APL, we decided to investigate how MLL5 affects ATRA-induced myeloid differentiation in APL, using the ATRA responsive NB4 cell line. The gene discussed is KMT2E; the disease is acute promyelocytic leukemia.